Information Provided By: 
Fly News Breaks for March 19, 2019
CPRX
Mar 19, 2019 | 12:21 EDT
Shares of Catalyst Pharmaceuticals are trading higher after the company's Q4 earnings call and comments from management that point toward a strong Firdapse launch, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Accrual of former EAP patients onto Catalyst Pathways has been quicker than expected and payer interactions appear to be progressing nicely, adds the analyst. He views his $41.0M 2019 sales estimate as "readily achievable" and maintains an Overweight rating on Catalyst Pharmaceuticals with a $7.50 price target.
News For CPRX From the Last 2 Days
There are no results for your query CPRX
